In this issue:
- Impact of lobular vs ductal histology on OS in mBC
- Estimation of breast cancer overdiagnosis
- A text message intervention for breast cancer survivors
- Low- vs high-level supervision of an exercise intervention
- Breast cancer costs by stage and subtype in NZ
- Trastuzumab deruxtecan vs trastuzumab emtansine
- The impact of young age on prognosis by breast cancer subtype
- OS with ribociclib + letrozole in advanced disease
- Adverse health effects up to 14 years after diagnosis
- Tucatinib + trastuzumabcapecitabine for pretreated HER2+ mBC ± brain metastases
Please login below to download this issue (PDF)